Paediatric essential thrombocythaemia: clinical and molecular features, diagnosis and treatment

Clinical evaluation of the European LeukemiaNet response criteria in patients with essential thrombocythemia treated with anagrelide

(2013) Juan Carlos Hernández-Boluda et al.   ANNALS OF HEMATOLOGY

Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial

(2013) H. Gisslinger et al.   BLOOD

MPL W515L mutation in pediatric essential thrombocythemia

(2013) Piero Farruggia et al.   PEDIATRIC BLOOD & CANCER

Correlation of blood counts with vascular complications in essential thrombocythemia: analysis of the prospective PT1 cohort

(2012) P. J. Campbell et al.   BLOOD

Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis)

(2012) T. Barbui et al.   BLOOD

Thrombocythemia and polycythemia in patients younger than 20 years at diagnosis: clinical and biologic features, treatment, and long-term outcome

(2012) F. Giona et al.   BLOOD

A prognostic model to predict survival in 867 World Health Organization-defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment

(2012) F. Passamonti et al.   BLOOD

Front-line therapy in polycythemia vera and essential thrombocythemia

(2012) Tiziano Barbui et al.   BLOOD REVIEWS

Linking Drugs to Obscure Illnesses: Lessons from Pure Red Cell Aplasia, Nephrogenic Systemic Fibrosis, and Reye’s Syndrome. A Report From the Southern Network on Adverse Reactions (SONAR)

(2012) Charles L. Bennett et al.   JOURNAL OF GENERAL INTERNAL MEDICINE

How to manage children and young adults with myeloproliferative neoplasms

(2012) T Barbui   LEUKEMIA

Myeloproliferative neoplasms 2012: The John M. Bennett 80th birthday anniversary lecture

(2012) Ayalew Tefferi   LEUKEMIA RESEARCH

Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients

(2011) A. Carobbio et al.   BLOOD

Advances in understanding the pathogenesis of familial thrombocythaemia

(2011) Luciana Teofili et al.   BRITISH JOURNAL OF HAEMATOLOGY

Philadelphia-Negative Classical Myeloproliferative Neoplasms: Critical Concepts and Management Recommendations From European LeukemiaNet

(2011) Tiziano Barbui et al.   JOURNAL OF CLINICAL ONCOLOGY

Survival and Disease Progression in Essential Thrombocythemia Are Significantly Influenced by Accurate Morphologic Diagnosis: An International Study

(2011) Tiziano Barbui et al.   JOURNAL OF CLINICAL ONCOLOGY

Treatment-Related Risk Factors for Transformation to Acute Myeloid Leukemia and Myelodysplastic Syndromes in Myeloproliferative Neoplasms

(2011) Magnus Björkholm et al.   JOURNAL OF CLINICAL ONCOLOGY

Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria

(2011) G Finazzi et al.   LEUKEMIA

Mutations profile of polycythemia vera and essential thrombocythemia among Japanese children

(2011) Olfat Ismael et al.   PEDIATRIC BLOOD & CANCER

Management of Essential Thrombocythemia

(2011) F. Cervantes   Hematology-American Society of Hematology Education Program

Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia

(2010) A. Alvarez-Larran et al.   BLOOD

Guideline for investigation and management of adults and children presenting with a thrombocytosis

(2010) Claire N. Harrison et al.   BRITISH JOURNAL OF HAEMATOLOGY

The Asn505 mutation of the c-MPL gene, which causes familial essential thrombocythemia, induces autonomous homodimerization of the c-Mpl protein due to strong amino acid polarity

(2009) J. Ding et al.   BLOOD

The mutantJAK2V617Fallele burden in children with essential thrombocythemia

(2009) Luciana Teofili et al.   BRITISH JOURNAL OF HAEMATOLOGY

Hereditary thrombocytosis caused by MPLSer505Asn is associated with a high thrombotic risk, splenomegaly and progression to bone marrow fibrosis

(2009) L. Teofili et al.   HAEMATOLOGICA

Reticulin Accumulation in Essential Thrombocythemia: Prognostic Significance and Relationship to Therapy

(2009) Peter J. Campbell et al.   JOURNAL OF CLINICAL ONCOLOGY

Pegylated Interferon Alfa-2a Yields High Rates of Hematologic and Molecular Response in Patients With Advanced Essential Thrombocythemia and Polycythemia Vera

(2009) Alfonso Quintás-Cardama et al.   JOURNAL OF CLINICAL ONCOLOGY

Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia

(2008) A. M. Vannucchi et al.   BLOOD

MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort

(2008) P. A. Beer et al.   BLOOD

A de novo splice donor mutation in the thrombopoietin gene causes hereditary thrombocythemia in a Polish family

(2008) K. Liu et al.   HAEMATOLOGICA

Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients

(2008) F. Passamonti et al.   HAEMATOLOGICA

Second malignancies in essential thrombocythemia (ET): a retrospective analysis of 331 patients with long-term follow-up from a single institution

(2008) Franca Radaelli et al.   Hematology

Life expectancy and prognostic factors in the classic BCR/ABL-negative myeloproliferative disorders

(2008) F Cervantes et al.   LEUKEMIA

Frequency and clinical features of theJAK2V617F mutation in pediatric patients with sporadic essential thrombocythemia

(2008) Takuya Nakatani et al.   PEDIATRIC BLOOD & CANCER

Most pediatric patients with essential thrombocythemia show hypersensitivity to erythropoietin in vitro, with rare JAK2 V617F-positive erythroid colonies

(2007) Jitka Veselovska et al.   LEUKEMIA RESEARCH